Grifols, a global leader in the development of plasma-derived therapies dedicated for more than 100 years to enhancing people’s health and well-being, finalized a USD 370 million transaction to acquire 25 U.S.-based plasma donation centers from BPL Plasma Inc., a subsidiary of Bio Products Laboratory Holdings Limited. The transaction has received the applicable regulatory clearances and will be financed with Grifols’ own resources, without issuing debt. In accordance with the company’s strategic plan to advance its plasma-collection leadership, this transaction expands, reinforces and diversifies Grifols’ already-robust network of centers and capacity to supply life-enhancing plasma-derived medicines to patients.
Read the full article: Grifols Acquires 25 U.S.-Based Plasma Centers from BPL //
Source: https://www.grifols.com/en/view-news/-/news/grifols-acquires-25-us-based-plasma-centers-from-bpl-ensuring-one-million-additional-liters-for-fractionation